EA201791839A1 - Диметоксифенильные ингибиторы везикулярного транспортера моноаминов 2 - Google Patents
Диметоксифенильные ингибиторы везикулярного транспортера моноаминов 2Info
- Publication number
- EA201791839A1 EA201791839A1 EA201791839A EA201791839A EA201791839A1 EA 201791839 A1 EA201791839 A1 EA 201791839A1 EA 201791839 A EA201791839 A EA 201791839A EA 201791839 A EA201791839 A EA 201791839A EA 201791839 A1 EA201791839 A1 EA 201791839A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitors
- dimetoxyphenilic
- vesicular transporter
- monoamine
- monoamine vesicular
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 title 1
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 title 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117654P | 2015-02-18 | 2015-02-18 | |
| PCT/US2016/018222 WO2016133989A1 (en) | 2015-02-18 | 2016-02-17 | Dimethoxyphenyl inhibitors of vesicular monoamine transporter 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201791839A1 true EA201791839A1 (ru) | 2018-02-28 |
Family
ID=56692737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791839A EA201791839A1 (ru) | 2015-02-18 | 2016-02-17 | Диметоксифенильные ингибиторы везикулярного транспортера моноаминов 2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10722479B2 (enExample) |
| EP (1) | EP3258926A4 (enExample) |
| JP (1) | JP2018507210A (enExample) |
| AR (1) | AR103728A1 (enExample) |
| BR (1) | BR112017017673A2 (enExample) |
| CA (1) | CA2976229A1 (enExample) |
| EA (1) | EA201791839A1 (enExample) |
| IL (1) | IL253901A0 (enExample) |
| MA (1) | MA41557A (enExample) |
| MX (1) | MX2017010567A (enExample) |
| TW (1) | TW201630871A (enExample) |
| WO (1) | WO2016133989A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10047077B2 (en) | 2016-04-13 | 2018-08-14 | Skyline Antiinfectives, Inc. | Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA852843B (en) | 1984-05-15 | 1985-11-27 | Warner Lambert Co | Bevantolol preparation |
| CA2653209A1 (en) * | 2006-05-26 | 2007-12-06 | Auspex Pharmaceuticals, Inc. | Deuterated aminoglycidyl compounds |
| CA2701638A1 (en) | 2007-04-02 | 2008-10-09 | Concert Pharmaceuticals Inc. | Pharmaceutical calcimimetics |
| US20100009950A1 (en) * | 2008-06-30 | 2010-01-14 | Auspex Pharmaceuticals, Inc. | Substituted ethanolamines |
| NZ591615A (en) * | 2008-09-18 | 2012-07-27 | Auspex Pharmaceuticals Inc | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US20100143287A1 (en) | 2008-12-09 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | Trifluoromethylphenyl modulators of calcium-sensing receptor |
| US20120003330A1 (en) * | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| JP6362601B2 (ja) * | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| JP6476174B2 (ja) * | 2013-06-19 | 2019-02-27 | ソム イノヴェーション バイオテック、ソシエダッド リミターダ | 運動過剰障害の予防および／または治療における使用のための治療剤 |
-
2016
- 2016-02-16 MA MA041557A patent/MA41557A/fr unknown
- 2016-02-17 US US15/550,152 patent/US10722479B2/en active Active
- 2016-02-17 MX MX2017010567A patent/MX2017010567A/es unknown
- 2016-02-17 EP EP16752959.3A patent/EP3258926A4/en not_active Withdrawn
- 2016-02-17 CA CA2976229A patent/CA2976229A1/en not_active Abandoned
- 2016-02-17 WO PCT/US2016/018222 patent/WO2016133989A1/en not_active Ceased
- 2016-02-17 JP JP2017543828A patent/JP2018507210A/ja active Pending
- 2016-02-17 EA EA201791839A patent/EA201791839A1/ru unknown
- 2016-02-17 BR BR112017017673A patent/BR112017017673A2/pt not_active Application Discontinuation
- 2016-02-18 AR ARP160100435A patent/AR103728A1/es unknown
- 2016-02-18 TW TW105104725A patent/TW201630871A/zh unknown
-
2017
- 2017-08-08 IL IL253901A patent/IL253901A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018507210A (ja) | 2018-03-15 |
| EP3258926A4 (en) | 2018-11-14 |
| TW201630871A (zh) | 2016-09-01 |
| MX2017010567A (es) | 2018-03-16 |
| AR103728A1 (es) | 2017-05-31 |
| CA2976229A1 (en) | 2016-08-25 |
| EP3258926A1 (en) | 2017-12-27 |
| IL253901A0 (en) | 2017-10-31 |
| US10722479B2 (en) | 2020-07-28 |
| WO2016133989A1 (en) | 2016-08-25 |
| MA41557A (fr) | 2017-12-26 |
| US20180036260A1 (en) | 2018-02-08 |
| BR112017017673A2 (pt) | 2018-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| EA201691512A1 (ru) | Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2 | |
| DK3328843T3 (da) | 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning | |
| DK3442973T3 (da) | Hidtil ukendte forbindelser som autotaxinhæmmere og farmaceutiske sammensætninger omfattende samme | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| DK3331864T3 (da) | 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| EA201790649A1 (ru) | Бензилзамещенные индазолы в качестве ингибиторов bub 1 | |
| CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
| EA201691421A1 (ru) | Гетероарилы и их применение | |
| DK3330259T3 (da) | 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne | |
| EA201891087A1 (ru) | Ингибиторы ret | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| MX2017014299A (es) | Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. | |
| DK3684333T3 (da) | Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| TR201810635T4 (tr) | Anti-jagged1 antikorları ve kullanım yöntemleri. | |
| EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| MX395032B (es) | Ciertos inhibidores de la proteína quinasa. | |
| EA201691412A1 (ru) | Гидроксиформамидные производные и их применение | |
| EA202091337A1 (ru) | Ингибиторы гистонацетилтрансфераз семейства myst |